Abstract:OBJECTIVETo study the inhibitory effect of altered collagen II (CII) 263-272 peptide (sub268-270) with three consecutive substitutions of TCR-contacting residues on joint inflammation and cartilage destruction in collagen-induced arthritis (CIA).METHODSThirty-two Lewis rats were injected intracutaneously with bovine collagen type II so as to establish models of arthritis and then were randomly divided into 4 equal groups to be injected intravenously with sub268-270 30 microg, 5 microg, or 1 microg and PBS twice a week for 3 weeks. The therapeutic effect of the altered peptide on arthritis was evaluated by arthritis score. After the treatment the rats were killed and their ankle joints were taken to undergo pathological examination to observe the existence of synovitis, pannus formation, cartilage damage, and bone erosion. Blood samples were collected to detect the serum cartilage oligomeric matrix protein (COMP). Cartilage proteoglycan-specific dye safranin O was used on the joint sections to observe the coloration of the dye in the cartilage.RESULTSThe arthritis score in rats treated by 30 microg altered CII peptide was (5.6 +/- 2.63), significantly lower than those of the 5 microg, 1 microg, and blank control groups [(9.67 +/- 5.61), (10.02 +/- 5.06), and (11.8 +/- 5.34) respectively, all P < 0.01]. The synovitis score of the 30 microg group was (1.11 +/- 0.43), significantly lower than those of the 5 microg, 1 microg, and blank control groups [(1.87 +/- 0.78), (2.11 +/- 0.83), and (2.25 +/- 0.73) respectively, all P < 0.01]. The pannus score of the 30 microg group was (1.11 +/- 0.43), significantly lower than those of the 5 microg, 1 microg, and blank control groups [(1.83 +/- 0.79), (2.07 +/- 0.91), and (2.27 +/- 0.71) respectively, all P < 0.01]. The cartilage damage score of the 30 microg group was 0.56 +/- 0.23), significantly lower than those of the 5 microg, 1 microg, and blank control groups [(1.91 +/- 0.83), (2.13 +/- 0.79), and (2.29 +/- 0.69) respectively, all P < 0.01]. The bone erosion score of the 30 microg group was (0.53 +/- 0.21), significantly lower than those of the 5 microg, 1 microg, and blank control groups [(1.71 +/- 0.67), (1.88 +/- 0.93), and (2.01 +/- 0.93) respectively, all P < 0.01]. The serum COMP of the 30 microg group was (2.21 +/- 0.76), significantly lower than those of the 5 microg, 1 microg, and blank control groups [(5.63 +/- 1.73), (6.04 +/- 1.76), and (7.00 +/- 1.46) respectively, all P < 0.01]. The content of safranin O (A value) in the joint section of the 30 microg group was (2.35 +/- 0.76), significantly higher than those of the 5 microg, 1 microg, and blank control groups [(1.57 +/- 0.63), (1.37 +/- 0.53), and (1.00 +/- 0.41) respectively, all P < 0.01].CONCLUSIONThe altered CII peptide sub268-270 effectively ameliorates CIA and inhibits the cartilage damage in CIA, and may modify the disease course of rheumatoid arthritis.

[Effect of Multiple Amino Acid Substitutions of Collagen II 263-272 on Collagen-Induced Arthritis].

Altered Collagen Ii 263-272 Peptide Immunization Induces Inhibition of Collagen-Induced Arthritis Through A Shift Toward Th2-Type Response

Inhibition of Cartilage Destruction in Collagen-Induced Arthritis by Altered CII 263-272 Peptide:Experiment with Rats

[Experiment Treatment of Collagen-Induced Arthritis in Rats with Recombinant Plasmid Containing Vasoactive Intestinal Peptide Gene].

Mucosal Administration of Altered CII263-272 Peptide Inhibits Collagen- Induced Arthritis

HLA-DRB1 binding CⅡ263-272 peptide inhibits collagen-induced arthritis

Mucosal administration of an altered CII263-272 peptide inhibits collagen-induced arthritis by suppression of Th1/Th17 cells and expansion of regulatory T cells

Altered Collagen II Peptides Inhibited T-cell Activation in Rheumatoid Arthritis.

Inhibition of Collagen-Induced Arthritis by HLA-DRβ1 Specific Non-T Cell Binding Peptide

The Inhibitory Effect of the Altered Collagen II Peptide on T Cell Activation in Patients with Rheumatoid Arthritis

Co-Expression of Il-18 Binding Protein and Il-4 Regulates Th1/Th2 Cytokine Response in Murine Collagen-Induced Arthritis

Oral Administration of Type-Ii Collagen Peptide 250–270 Suppresses Specific Cellular and Humoral Immune Response in Collagen-Induced Arthritis

Superior Molecularly Altered Influenza Virus Hemagglutinin Peptide 308-317 Inhibits Collagen-Induced Arthritis by Inducing CD4+ Treg Cell Expansion.

A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice

Altered influenza virus haemagglutinin (HA)-derived peptide is potent therapy for CIA by inducing Th1 to Th2 shift

[Study of the Humoral Immune Suppression of Recombinant Human Collagen Type II Peptide 250-270].

Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope.

Therapeutic effects of lactosyl derivative Gu-4 in a collagen-induced arthritis rat model

Oral Administration of Type II Collagen Suppresses Pro-Inflammatory Mediator Production by Synoviocytes in Rats with Adjuvant Arthritis.

A Triple Altered Collagen II Peptide with Consecutive Substitutions of TCR Contacting Residues Inhibits Collagen-Induced Arthritis

[Effect of Interleukin I Receptor Antigonist Gene Therapy on Arthritis Induced by Type II Collagen in Mice].